Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, Calif., has announced that it will acquire Oobli Inc., a Davis, Calif.-based developer of fermentation-derived sweet proteins. Oobli’s ingredients are designed to help food and beverage brands reduce sugar while maintaining sweet taste.
The transaction brings together Amyris’s scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. The company described the acquisition as a strategic commercial and technology expansion that would accelerate its work in protein- and peptide-based solutions across end markets.
Complementary platforms
“In Oobli, we see a commercial and technology platform that is a great complement to our own,” Amyris Chief Executive Officer Kathy Fortmann said. She said Oobli is positioned to change how sweetness reaches the market, and that Amyris aims to use its commercial scale and resources to accelerate that effort.
Fortmann also said that combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden the combined company’s capabilities in food and beverage, personal care, flavor and fragrance, agriculture and other areas. She framed the potential in terms of helping customers innovate rather than as a completed expansion.
Oobli’s commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process for producing sweet proteins that are naturally found in rare fruits and berries near the equator. Oobli describes its sweet proteins as the first of their kind in the sugar-reduction category.
How the proteins work
According to Oobli, sweet proteins are hundreds to thousands of times sweeter than sugar. They bind directly to sweet taste receptors and are metabolized by the body as protein. The company says this delivers sweetness without gut disruption or blood sugar spikes.
Oobli’s portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor.
The company is targeting applications across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery. It points to growing consumer awareness of metabolic health and the benefits of sugar reduction as factors that could give brands a new tool for lowering sugar across a broad range of categories.
Scale and market ambition
Oobli Chief Executive Officer Ali Wing said the company has long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann said Amyris has seen biomanufactured solutions succeed when they align with consumer demand and market needs. She said Oobli’s platform does that by offering brands a way to address sweet taste, sugar reduction and clean label at the same time. She added that Amyris looks forward to welcoming the Oobli team and realizing synergies between the two platforms.
The acquisition is expected to close in the coming weeks. As Oobli’s sweet protein portfolio continues to expand within Amyris, the companies said all existing customer commitments and brand partnerships will continue to be honored without interruption.
